Osiris Therapeutics to Hold Call on Grafix Trial Aug. 13th at 9AM EDT

Osiris Therapeutics, Inc.

today announced that C. Randal Mills, Ph.D., President and Chief Executive Officer, will host a conference call to discuss the results of the interim analysis of its multicenter, randomized, controlled trial evaluating the efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers. The call will be held tomorrow, August 13, 2013 at 9:00 a.m. ET. To access the webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm. Alternatively, callers may participate in the conference call by dialing (877) 303-6133 (U.S. participants) or (970) 315-0493 (international participants). An archive of the webcast will be available approximately two hours after the completion of the call. To access the archived webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm.